(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients.
The Boston-based biotechnology company said the immersive mobile video game treatment, EndeavorOTC, is now available without prescription in the US.
Endeavor OTC is built on the same technology as Akili's EndeavouRx, a US Food & Drug Administration-authorised video game treatment used to treat children with ADHD.
The launch of EndeavourOTC comes after it was announced last month that the treatment had "significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms," with 83% of clinical trial participants stating improvements in their focus. Over one-third of participants also said they no longer exhibited an attention deficit following treatment. An improvement in quality of life was reported by 73% of participants.
Akili is an Irving, Texas-based developer of cognitive treatments using game-changing technologies.
Shares in PureTech were up 0.9% at 238.00 pence each in London on Wednesday afternoon.
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
PureTech (PRTC)